推荐产品
![O-(3-羧丙基)-O′-[2-(3-巯基丙酰氨基)乙基]-聚乙二醇 Mw 5000](/deepweb/assets/sigmaaldrich/product/structures/271/277/d02536f0-83d7-4416-9cea-f6213e09fe85/640/d02536f0-83d7-4416-9cea-f6213e09fe85.png)
![(R)-1-{(RP)-2-[2-(二苯基膦)苯基]二茂铁基}乙基双[3,5-双-(三氟甲基)苯基]膦 ≥97%](/deepweb/assets/sigmaaldrich/product/structures/185/002/97358faf-b2d8-4de5-9315-73b6a8b3ae26/640/97358faf-b2d8-4de5-9315-73b6a8b3ae26.png)
![O-[2-(3-巯基丙酰基氨基)乙基]-O′-甲基聚乙二醇 5,000](/deepweb/assets/sigmaaldrich/product/structures/293/792/95ae9557-6907-4575-8903-f5b87ada86e2/640/95ae9557-6907-4575-8903-f5b87ada86e2.png)
形狀
powder
分子量
Mw 3000
反應適用性
reagent type: cross-linking reagent
Ω-end
thiol
α-end
carboxylic acid
儲存溫度
−20°C
正在寻找类似产品? 访问 产品对比指南
包裝
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
Eyeshields, Gloves, type N95 (US)
其他客户在看
商品
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
实验方案
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门